Globus Medical stock hits 52-week low at 70.39 USD
Globus Medical's stock fell to a 52-week low of 70.39 USD, signaling significant challenges for the company. In the past year, the stock has dropped by 15.55%, yet InvestingPro data indicates there may be potential undervaluation. The company's price-to-earnings (P/E) ratio is 17.4, and one of eight InvestingPro Tips suggests the stock is trading at a low P/E relative to expected earnings growth.
This decline mirrors broader difficulties in the medical technology sector, as investors navigate volatility and sector-specific issues. The 52-week low raises concerns for stakeholders, urging careful monitoring of future performance and strategic changes. For a deeper understanding of GMED's valuation, investors can refer to the full Pro Research Report available on InvestingPro, which offers analysis for this and more than 1,400 other US equities.
Recently, Globus Medical disclosed its Q3 2026 financial results, with revenue at $763.7 million, falling short of expectations. The company's non-GAAP earnings per share were $1.23, narrowly beating the projected $1.20. The shortfall was due to delayed product launches and a 25.7% sales drop at its Nevro unit. Consequently, BMO Capital reduced its rating to Market Perform with a price target of $78.00, while BTIG kept its Neutral stance, emphasizing the revenue miss.
These events have led to a reassessment of Globus Medical’s financial expectations for the year. This report was produced with AI assistance and edited for accuracy.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Innoviva stock hits 52-week low at 18.6 USD investing.com